171 related articles for article (PubMed ID: 8556529)
1. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies.
Cleare W; Mukherjee S; Spitzer ED; Casadevall A
Clin Diagn Lab Immunol; 1994 Nov; 1(6):737-40. PubMed ID: 8556529
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
4. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
5. Antibody interactions with the capsule of Cryptococcus neoformans.
Feldmesser M; Rivera J; Kress Y; Kozel TR; Casadevall A
Infect Immun; 2000 Jun; 68(6):3642-50. PubMed ID: 10816523
[TBL] [Abstract][Full Text] [Related]
6. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
7. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
[TBL] [Abstract][Full Text] [Related]
8. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1995 Sep; 63(9):3353-9. PubMed ID: 7642262
[TBL] [Abstract][Full Text] [Related]
9. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcus neoformans infection can elicit protective antibodies in mice.
Mukherjee J; Scharff MD; Casadevall A
Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
[TBL] [Abstract][Full Text] [Related]
12. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
14. Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.
Ikeda R; Nishimura S; Nishikawa A; Shinoda T
Clin Diagn Lab Immunol; 1996 Jan; 3(1):89-92. PubMed ID: 8770510
[TBL] [Abstract][Full Text] [Related]
15. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
16. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
17. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins.
Mukherjee S; Feldmesser M; Casadevall A
J Infect Dis; 1996 May; 173(5):1222-31. PubMed ID: 8627076
[TBL] [Abstract][Full Text] [Related]
18. Biological activity of a mouse-human chimeric immunoglobulin G2 antibody to Cryptococcus neoformans polysaccharide.
Westin Kwon K; Lendvai N; Morrison S; Trinh KR; Casadevall A
Clin Diagn Lab Immunol; 2002 Jan; 9(1):201-4. PubMed ID: 11777857
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
Mukherjee S; Lee SC; Casadevall A
Infect Immun; 1995 Feb; 63(2):573-9. PubMed ID: 7822024
[TBL] [Abstract][Full Text] [Related]
20. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.
Dromer F; Salamero J; Contrepois A; Carbon C; Yeni P
Infect Immun; 1987 Mar; 55(3):742-8. PubMed ID: 3546139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]